Kala Pharmaceuticals Inc. (KALA) and Auris Medical Holding Ltd. (NASDAQ:EARS) Contrasting side by side

Both Kala Pharmaceuticals Inc. (NASDAQ:KALA) and Auris Medical Holding Ltd. (NASDAQ:EARS) are each other’s competitor in the Biotechnology industry. Thus the contrast of their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kala Pharmaceuticals Inc. 6 41.48 N/A -2.74 0.00
Auris Medical Holding Ltd. 4 0.00 N/A -21.61 0.00

Table 1 highlights Kala Pharmaceuticals Inc. and Auris Medical Holding Ltd.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 demonstrates the return on assets, net margins and return on equity of Kala Pharmaceuticals Inc. and Auris Medical Holding Ltd.

Net Margins Return on Equity Return on Assets
Kala Pharmaceuticals Inc. 0.00% -104.2% -54.1%
Auris Medical Holding Ltd. 0.00% 0% -111.7%

Liquidity

10.3 and 9.9 are the respective Current Ratio and a Quick Ratio of Kala Pharmaceuticals Inc. Its rival Auris Medical Holding Ltd.’s Current and Quick Ratios are 1.3 and 1.3 respectively. Kala Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Auris Medical Holding Ltd.

Analyst Recommendations

Kala Pharmaceuticals Inc. and Auris Medical Holding Ltd. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Kala Pharmaceuticals Inc. 0 0 2 3.00
Auris Medical Holding Ltd. 0 0 0 0.00

Kala Pharmaceuticals Inc. has an average target price of $13.5, and a 221.43% upside potential.

Institutional & Insider Ownership

Institutional investors owned 83.4% of Kala Pharmaceuticals Inc. shares and 15.1% of Auris Medical Holding Ltd. shares. Kala Pharmaceuticals Inc.’s share owned by insiders are 4.25%. Comparatively, 16.57% are Auris Medical Holding Ltd.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Kala Pharmaceuticals Inc. 3.89% -7.98% -20.65% 10.11% -51.96% 20.25%
Auris Medical Holding Ltd. 7.66% 8.86% -33.71% -65.68% -43.59% -67.65%

For the past year Kala Pharmaceuticals Inc. has 20.25% stronger performance while Auris Medical Holding Ltd. has -67.65% weaker performance.

Summary

Kala Pharmaceuticals Inc. beats on 7 of the 8 factors Auris Medical Holding Ltd.

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles technology. The companyÂ’s product candidates include KPI-121 1.0%, which has completed Phase 3 clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-121 0.25% that is in Phase 3 clinical trials for the temporary relief of the signs and symptoms of dry eye disease. It also develops KPI-285, a receptor kinase inhibitor, which is in preclinical studies for the treatment of various retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Waltham, Massachusetts.

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. The company is also developing AM-125 for the treatment of vestibular disorders; and other pre-clinical stage products comprising AM-102 and AM-123. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.